<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680339</url>
  </required_header>
  <id_info>
    <org_study_id>42</org_study_id>
    <nct_id>NCT03680339</nct_id>
  </id_info>
  <brief_title>The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS</brief_title>
  <official_title>The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      • Patients will be divided into two groups 100 patients will receive routine ecbolics (for
      example oxytocin) after delivery of baby The 100 patients will receive routine ecbolics (for
      example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with
      catheterization and another 400 microgram rectally after closure of abdomen

      Then we will compare between two groups regarding

        -  Intaoperative blood loss

        -  Risk of Postpartum hemorraghe in the first 24 hrs

        -  HB pre and postoperative for all patients

      Intraoperative blood loss will be estimated by the number and weight of soaked towels and
      amount of blood in suction unit
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      • Patients will be divided into two groups 100 patients will receive routine ecbolics (for
      example oxytocin) after delivery of baby The 100 patients will receive routine ecbolics (for
      example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with
      catheterization and another 400 microgram rectally after closure of abdomen

      Then we will compare between two groups regarding

        -  Intaoperative blood loss

        -  Risk of Postpartum hemorraghe in the first 24 hrs

        -  HB pre and postoperative for all patients

      Intraoperative blood loss will be estimated by the number and weight of soaked towels and
      amount of blood in suction unit
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postpartum hemorrhage</measure>
    <time_frame>24 hours after cesarean section</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Post Partum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Routine ecbolic group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 patients will receive routine ecbolics ( oxytocin) after delivery of baby</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cesarean section</intervention_name>
    <description>CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers</description>
    <arm_group_label>Misoprostol group</arm_group_label>
    <arm_group_label>Routine ecbolic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen</description>
    <arm_group_label>Misoprostol group</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>10 IU of oxytocin with fetal delivery</description>
    <arm_group_label>Misoprostol group</arm_group_label>
    <arm_group_label>Routine ecbolic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        women attending for elective CS.

          -  Age between 20-35 years.

          -  Normal placental site

          -  Normal coagulation profile

          -  Full term pregnancies(above 37 wks)

          -  Medically free

          -  Spinal anesthesia

          -  Living baby

          -  Average liquor by U/S

        Exclusion Criteria:

          -  • Women attending for emergency CS

               -  .age below 20 or above 35

               -  Abnormal placentation (Placenta previa,accrete,increta or percreta)

               -  Women with coagulopathy

               -  Preterm pregnancies (before 37 wks)

               -  Medical disorder (Hypertension,Diabetes, Endocrinal disorder)

               -  General anathesia

               -  IUFD

               -  Oligo or polyhydraminos by U/S
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed maged, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed maged, MD</last_name>
    <phone>+2001005227404</phone>
    <email>prof.ahmedmaged@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Shalaby, MD</last_name>
    <email>mohamed_shalaby85@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Maged</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

